The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...
1d
The 'smart money' fled software stocks after that viral AI doomsday report. Here's where it's going.
The Citrini selloff wasn't panic - it was an X-ray of the tech sector A recent bombshell report on AI tech tanked shares of vulnerable software and financial services companies. Citrini Research's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results